Redeye provides its first take on Hansa Biopharma's Q2 report. Total revenue was SEK48.1m (SEK49.1m in Q2 2025), up 39% sequentially from SEK34.6m in Q1 2026 and just around 9% below our previous forecast SEK53m. Operating costs were higher than we had expected, partly due to one-offs and non-cash costs.
LÄS MER
